Diagnostic tools of Waldenström ´s macroglobulinemia - best possibilities for non-invasive and long-term disease monitoring
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F17%3AE0106567" target="_blank" >RIV/00843989:_____/17:E0106567 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.14735/amko20172S81" target="_blank" >http://dx.doi.org/10.14735/amko20172S81</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.14735/amko20172S81" target="_blank" >10.14735/amko20172S81</a>
Alternative languages
Result language
angličtina
Original language name
Diagnostic tools of Waldenström ´s macroglobulinemia - best possibilities for non-invasive and long-term disease monitoring
Original language description
Waldenström’s macroglobulinemia (WM) is a B-cell malignancy characterized by high level of monoclonal immunoglobulin M (IgM) paraprotein in blood serum and associated with the bone marrow infiltration by malignant cells with lymphoplasmacytic differentiation. WM remains incurable advances in therapy. Most of WM cases are associated with a somatic point mutation L265P in MYD88. Significantly higher risk of progression from the IgM monoclonal gammopathy of undetermined significance (IgM MGUS) to WM for patients with mutated MYD88 gene suggests that this mutation is an early oncogenic event and plays a central role in development of malignant clones. The second, most prevalent mutation in WM is found in the CXCR4 gene and is often associated with drug resistance and aggressive disease presentation. Therefore, detection of these mutations (MYD88L265P and CXCR4S338X) could be useful diagnostic and prognostic tool for the patients with WM. While detection of these mutations in bone marrow sample is common, the aim of our study was to compare sensitivity of detection of mutation from different cell fraction from peripheral blood and bone marrow. The results show possibility to describe MYD88 and CXCR4 mutation status even from peripheral blood sample (sensitivity for MYD88L265P was 100%, for CXCR4S338X 91%), which significantly facilitate material collection. Moreover, comparable detection sensitivity of these mutations in bone marrow and peripheral blood samples examined before and during the therapy offers a promising tool for more routine diagnostic and monitoring of disease progression.
Czech name
—
Czech description
—
Classification
Type
J<sub>SC</sub> - Article in a specialist periodical, which is included in the SCOPUS database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Klinická onkologie
ISSN
0862-495X
e-ISSN
1802-5307
Volume of the periodical
30
Issue of the periodical within the volume
suppl.2
Country of publishing house
CZ - CZECH REPUBLIC
Number of pages
1
Pages from-to
2s81-2s91
UT code for WoS article
—
EID of the result in the Scopus database
2-s2.0-85029470000